Novo Nordisk A/S is to pay an undisclosed amount of money to Evotec SE to gain access to the German company’s cell therapy technology and manufacturing capacity for its experimental therapies in a number of indications including diabetes. The collaboration, announced on 26 September, is an expansion of the Danish company’s platform technologies which are currently dominated by insulins and peptide therapies for obesity. Novo currently has cell therapy programmes under investigation for chronic heart failure, Parkinson’s disease and Type 1 diabetes.
